Individualized Treatments Acts
From Wikipedia, the free encyclopedia
Right-to-Try 2.0 (RtT2) laws are United States state laws created by Individualized Treatments Acts with the intent to allow terminally ill patients access to experimental therapies (drugs, biologics, peptides, devices) that have not completed Phase I testing.[1] Before right-to-try laws, patients needed FDA approval to use experimental drugs. State and then federal Right-to-try laws gave this access for therapies that that have completed Phase I testing.
As of 2025, 15 U.S. states had passed right to try 2.0 laws: [2] Arizona, April 2022; [3][4] Texas, June 2025.[2] The framers of these laws argue that this allows for individualized treatments not permitted under Right-to-try law.
